Clinical Trial Update: Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) [Phase 4]

View source ↗

Summary

Open-label, single-arm Phase 4 trial evaluating everolimus in patients with metastatic renal cell carcinoma after failure of the first VEGF-targeted therapy; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: iOMEDICO AG | Conditions: Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy | Phase 4 | Status: COMPLETED